KR102463844B1 - Cd3 결합 도메인을 가지는 다량체 il-15 기반 분자의 구성 및 특성규명 - Google Patents

Cd3 결합 도메인을 가지는 다량체 il-15 기반 분자의 구성 및 특성규명 Download PDF

Info

Publication number
KR102463844B1
KR102463844B1 KR1020187037953A KR20187037953A KR102463844B1 KR 102463844 B1 KR102463844 B1 KR 102463844B1 KR 1020187037953 A KR1020187037953 A KR 1020187037953A KR 20187037953 A KR20187037953 A KR 20187037953A KR 102463844 B1 KR102463844 B1 KR 102463844B1
Authority
KR
South Korea
Prior art keywords
fusion protein
cells
domain
2b8t2m
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020187037953A
Other languages
English (en)
Korean (ko)
Other versions
KR20190016979A (ko
Inventor
바이 리우
피터 로데
씨. 웡 힝
Original Assignee
알토 바이오사이언스 코포레이션
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 알토 바이오사이언스 코포레이션 filed Critical 알토 바이오사이언스 코포레이션
Priority to KR1020227036271A priority Critical patent/KR20220148306A/ko
Publication of KR20190016979A publication Critical patent/KR20190016979A/ko
Application granted granted Critical
Publication of KR102463844B1 publication Critical patent/KR102463844B1/ko
Assigned to 알토 바이오사이언스 엘엘씨 reassignment 알토 바이오사이언스 엘엘씨 권리의 전부이전등록 Assignors: 알토 바이오사이언스 코포레이션
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • C07K14/5443—IL-15
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/715—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons
    • C07K14/7155—Receptors; Cell surface antigens; Cell surface determinants for cytokines; for lymphokines; for interferons for interleukins [IL]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2887—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against CD20
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/524—CH2 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C07K2317/526—CH3 domain
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732—Antibody-dependent cellular cytotoxicity [ADCC]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2318/00—Antibody mimetics or scaffolds
    • C07K2318/20—Antigen-binding scaffold molecules wherein the scaffold is not an immunoglobulin variable region or antibody mimetics
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/33—Fusion polypeptide fusions for targeting to specific cell types, e.g. tissue specific targeting, targeting of a bacterial subspecies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/70—Fusion polypeptide containing domain for protein-protein interaction
    • C07K2319/74—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor
    • C07K2319/75—Fusion polypeptide containing domain for protein-protein interaction containing a fusion for binding to a cell surface receptor containing a fusion for activation of a cell surface receptor, e.g. thrombopoeitin, NPY and other peptide hormones

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Cell Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Transplantation (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
KR1020187037953A 2016-05-27 2017-05-26 Cd3 결합 도메인을 가지는 다량체 il-15 기반 분자의 구성 및 특성규명 Active KR102463844B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020227036271A KR20220148306A (ko) 2016-05-27 2017-05-26 Cd3 결합 도메인을 가지는 다량체 il-15 기반 분자의 구성 및 특성규명

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662342311P 2016-05-27 2016-05-27
US62/342,311 2016-05-27
US201662397236P 2016-09-20 2016-09-20
US62/397,236 2016-09-20
PCT/US2017/034656 WO2017205726A1 (en) 2016-05-27 2017-05-26 Construction and characterization of multimeric il-15-based molecules with cd3 binding domains

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020227036271A Division KR20220148306A (ko) 2016-05-27 2017-05-26 Cd3 결합 도메인을 가지는 다량체 il-15 기반 분자의 구성 및 특성규명

Publications (2)

Publication Number Publication Date
KR20190016979A KR20190016979A (ko) 2019-02-19
KR102463844B1 true KR102463844B1 (ko) 2022-11-08

Family

ID=60412970

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020187037953A Active KR102463844B1 (ko) 2016-05-27 2017-05-26 Cd3 결합 도메인을 가지는 다량체 il-15 기반 분자의 구성 및 특성규명
KR1020227036271A Withdrawn KR20220148306A (ko) 2016-05-27 2017-05-26 Cd3 결합 도메인을 가지는 다량체 il-15 기반 분자의 구성 및 특성규명

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020227036271A Withdrawn KR20220148306A (ko) 2016-05-27 2017-05-26 Cd3 결합 도메인을 가지는 다량체 il-15 기반 분자의 구성 및 특성규명

Country Status (7)

Country Link
US (1) US10865230B2 (https=)
EP (1) EP3464352B1 (https=)
JP (1) JP7037506B2 (https=)
KR (2) KR102463844B1 (https=)
CN (2) CN109496217B (https=)
AU (1) AU2017271593B2 (https=)
WO (1) WO2017205726A1 (https=)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK2160401T3 (da) 2007-05-11 2014-10-20 Altor Bioscience Corp Fusionsmolekyler og il-15-varianter
CN107880136B (zh) 2010-09-21 2021-11-12 阿尔托生物科学有限公司 多聚体il-15可溶性融合分子与其制造与使用方法
US11053299B2 (en) 2010-09-21 2021-07-06 Immunity Bio, Inc. Superkine
SI3094351T1 (sl) * 2014-01-15 2022-05-31 Kadmon Corporation, Llc Imunomodulatorna sredstva
CA3151221C (en) 2014-06-30 2026-01-13 Altor Bioscience Corporation Il-15-based molecules and methods of use thereof
AU2017271593B2 (en) 2016-05-27 2021-04-22 Altor Bioscience Corporation Construction and characterization of multimeric IL-15-based molecules with CD3 binding domains
JP7185530B2 (ja) 2016-06-13 2022-12-07 トルク セラピューティクス， インコーポレイテッド 免疫細胞機能を促進するための方法および組成物
CN118562016A (zh) 2016-10-21 2024-08-30 艾尔特生物科技公司 基于多聚体il-15的分子
JP7285828B2 (ja) 2017-09-05 2023-06-02 トルク セラピューティクス， インコーポレイテッド 治療用タンパク質組成物ならびにその作製および使用方法
AU2018385699B2 (en) * 2017-12-14 2024-08-15 Regeneron Pharmaceuticals, Inc. Daric interleukin receptors
TW201938196A (zh) * 2018-01-18 2019-10-01 美商南特生物科學股份有限公司 融合蛋白擴展
JP2021514625A (ja) * 2018-03-01 2021-06-17 グリコトープ ゲーエムベーハー 抗ｍｕｃ１抗体およびｉｌ−１５を含む融合タンパク質構築物
TW202003011A (zh) 2018-03-26 2020-01-16 美商艾爾特生物科技責任有限公司 抗ＰＤＬ１、ＩＬ－１５及ＴＧＦ－β受體組合分子
US11267866B2 (en) 2018-04-04 2022-03-08 Nant Holdings Ip, Llc Immunoglobulin complex comprising interleukin-15
WO2020037120A1 (en) 2018-08-16 2020-02-20 Nantbio, Inc. Il7-il15 txm compositions and methods
US12331320B2 (en) 2018-10-10 2025-06-17 The Research Foundation For The State University Of New York Genome edited cancer cell vaccines
IL322315A (en) 2019-05-14 2025-09-01 Provention Bio Inc Methods and preparations for preventing type 1 diabetes
WO2021041886A1 (en) * 2019-08-29 2021-03-04 Nantbio, Inc. Modified n-810 and methods therefor
US20230097573A1 (en) * 2019-10-16 2023-03-30 Lg Chem, Ltd. Neonatal fc receptor binding affimers
CN111690069B (zh) * 2019-11-13 2022-04-19 中国科学技术大学 一种IL-15/SuIL-15Rα-mFc-γ4复合体蛋白及其构造方法、应用
CN113135996A (zh) * 2019-12-09 2021-07-20 启愈生物技术(上海)有限公司 一种双特异抗体及其应用
AU2021287998B2 (en) 2020-06-11 2026-03-12 Benaroya Research Institute At Virginia Mason Methods and compositions for preventing type 1 diabetes
CN114106195B (zh) * 2020-08-27 2024-09-17 盛禾(中国)生物制药有限公司 一种多功能融合蛋白及其用途
WO2022042576A1 (zh) * 2020-08-27 2022-03-03 盛禾(中国)生物制药有限公司 一种多功能融合蛋白及其用途
US20230405122A1 (en) * 2020-11-24 2023-12-21 City Of Hope Compositions and uses of psca targeted chimeric antigen receptor modified cells
CN112795543B (zh) * 2021-02-04 2022-09-27 华中农业大学 杂交瘤细胞株及其分泌的抗草鱼IL-15Rα单克隆抗体和应用
BR112023021886A8 (pt) * 2021-04-22 2024-01-09 Guangdong Fapon Biopharma Inc Polipeptídeo de fusão biespecífico multifuncional
US12565529B2 (en) 2021-05-24 2026-03-03 Provention Bio, Inc. Methods for treating type 1 diabetes
JP7734994B2 (ja) * 2021-06-02 2025-09-08 クレ バイオテクノロジ （シャンハイ） カンパニー リミテッド 抗ｃｄ３抗体変異体、融合タンパク質および適用
WO2023006082A1 (zh) * 2021-07-30 2023-02-02 启愈生物技术(上海)有限公司 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
CN116143942A (zh) * 2021-09-09 2023-05-23 启愈生物技术(上海)有限公司 抗原靶向、抗cd16a和免疫效应细胞激活三功能融合蛋白及其应用
CN115806628A (zh) * 2022-08-03 2023-03-17 深圳市先康达生命科学有限公司 一种自分泌IL-15与anti-TIGIT结合的融合蛋白及其应用
WO2024197709A1 (zh) * 2023-03-30 2024-10-03 中国科学院深圳先进技术研究院 一种t细胞衔接器及其制备方法和应用
AU2024269870A1 (en) * 2023-05-05 2025-11-20 Board Of Regents, The University Of Texas System Multi-receptor natural killer cells

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996032478A1 (en) 1995-04-14 1996-10-17 Genentech, Inc. Altered polypeptides with increased half-life
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO2008143794A1 (en) 2007-05-11 2008-11-27 Altor Bioscience Corporation Fusion molecules and il-15 variants
US20120177595A1 (en) 2010-09-21 2012-07-12 Altor Bioscience Corporation Multimeric il-15 soluble fusion molecules and methods of making and using same

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5116964A (en) 1989-02-23 1992-05-26 Genentech, Inc. Hybrid immunoglobulins
WO1994004689A1 (en) 1992-08-14 1994-03-03 The Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services Recombinant toxin with increased half-life
US5747654A (en) 1993-06-14 1998-05-05 The United States Of America As Represented By The Department Of Health And Human Services Recombinant disulfide-stabilized polypeptide fragments having binding specificity
US5541087A (en) 1994-09-14 1996-07-30 Fuji Immunopharmaceuticals Corporation Expression and export technology of proteins as immunofusins
US5534592A (en) 1995-09-22 1996-07-09 The Goodyear Tire & Rubber Company High performance blend for tire treads
US8772451B2 (en) 2003-11-10 2014-07-08 Altor Bioscience Corporation Soluble TCR molecules and methods of use
EP1586585A1 (de) * 2004-04-14 2005-10-19 F. Hoffmann-La Roche Ag Expressionssystem zur Herstellung von IL-15/Fc-Fusionsproteinen und ihre Verwendung
CA2697612A1 (en) * 2007-08-28 2009-03-12 Biogen Idec Ma Inc. Anti-igf-1r antibodies and uses thereof
JOP20200236A1 (ar) 2012-09-21 2017-06-16 Regeneron Pharma الأجسام المضادة لمضاد cd3 وجزيئات ربط الأنتيجين ثنائية التحديد التي تربط cd3 وcd20 واستخداماتها
JP2016531100A (ja) * 2013-07-12 2016-10-06 ザイムワークス，インコーポレイテッド 二重特異的なｃｄ３及びｃｄ１９抗原結合構築物
CA3151221C (en) 2014-06-30 2026-01-13 Altor Bioscience Corporation Il-15-based molecules and methods of use thereof
WO2016018920A1 (en) * 2014-07-29 2016-02-04 Admune Therapeutics Llc Il-15 and il-15ralpha heterodimer dose escalation regimens for treating conditions
KR20180125435A (ko) 2015-09-25 2018-11-23 알토 바이오사이언스 코포레이션 이식편 대 종양 활성을 현저하게 향상시키는 인터루킨-15 수퍼아고니스트
AU2017271593B2 (en) 2016-05-27 2021-04-22 Altor Bioscience Corporation Construction and characterization of multimeric IL-15-based molecules with CD3 binding domains
US20190048055A1 (en) 2017-03-31 2019-02-14 Altor Bioscience Corporation Alt-803 in combination with anti-cd38 antibody for cancer therapies

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996032478A1 (en) 1995-04-14 1996-10-17 Genentech, Inc. Altered polypeptides with increased half-life
WO1997034631A1 (en) 1996-03-18 1997-09-25 Board Of Regents, The University Of Texas System Immunoglobin-like domains with increased half lives
WO2008143794A1 (en) 2007-05-11 2008-11-27 Altor Bioscience Corporation Fusion molecules and il-15 variants
US20090324538A1 (en) 2007-05-11 2009-12-31 Altor Bioscience Corporation Fusion molecules and IL-15 variants
US20120177595A1 (en) 2010-09-21 2012-07-12 Altor Bioscience Corporation Multimeric il-15 soluble fusion molecules and methods of making and using same
US20140205560A1 (en) 2010-09-21 2014-07-24 Altor Bioscience Corporation Multimeric il-15 soluble fusion molecules and methods of making and using same

Also Published As

Publication number Publication date
EP3464352A4 (en) 2019-10-23
US20170342119A1 (en) 2017-11-30
EP3464352A1 (en) 2019-04-10
KR20190016979A (ko) 2019-02-19
AU2017271593A1 (en) 2018-12-13
CN117362450A (zh) 2024-01-09
JP2019519227A (ja) 2019-07-11
WO2017205726A1 (en) 2017-11-30
US10865230B2 (en) 2020-12-15
CN109496217B (zh) 2023-10-20
JP7037506B2 (ja) 2022-03-16
CA3025343A1 (en) 2017-11-30
CN109496217A (zh) 2019-03-19
AU2017271593B2 (en) 2021-04-22
KR20220148306A (ko) 2022-11-04
EP3464352B1 (en) 2021-03-24

Similar Documents

Publication Publication Date Title
KR102463844B1 (ko) Cd3 결합 도메인을 가지는 다량체 il-15 기반 분자의 구성 및 특성규명
US11318201B2 (en) Multimeric IL-15-based molecules
KR102739572B1 (ko) Il-12 및 il-18로의 il-15-기반 융합
CN111867612B (zh) 抗PDL1、IL-15和TGF-β受体组合分子
CA3025343C (en) Construction and characterization of multimeric il-15-based molecules with cd3 binding domains
HK40007105B (en) Construction and characterization of multimeric il-15-based molecules with cd3 binding domains
HK40007105A (en) Construction and characterization of multimeric il-15-based molecules with cd3 binding domains
HK40014316B (en) Multimeric il-15-based molecules
HK40014316A (en) Multimeric il-15-based molecules

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20181227

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20200512

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20211129

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20220805

A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20221018

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20221101

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20221102

End annual number: 3

Start annual number: 1

PG1601 Publication of registration